Clinical Trials Logo

Lung Metastases clinical trials

View clinical trials related to Lung Metastases.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05808790 Not yet recruiting - Clinical trials for Colorectal Cancer Metastatic

Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy

COPPER
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

COPPER is an international, multicenter, parallel-arm, phase III randomized controlled trial comparing two local treatment strategies (SABR or metastasectomy) for patients with an indication for local treatment for limited (max. three) colorectal pulmonary metastases

NCT ID: NCT04888806 Not yet recruiting - Liver Metastases Clinical Trials

A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

Currently, comprehensive treatments for liver metastasis/pulmonary metastasis that cannot reach NED include systemic chemotherapy, interventional chemotherapy, molecular targeted therapy, immunotherapy, and local treatments (ablation therapy, radiation therapy, etc.) for liver metastases. Combination therapy model of local ablation, systemic chemotherapy, and anti-PD -1 monoclonal antibody hopefully can prolong patient survival. This trial will evaluate the effectiveness and safety of carrelizumab combined with microwave ablation and chemotherapy in the treatment of colorectal cancer liver metastasis/pulmonary metastasis

NCT ID: NCT04704960 Not yet recruiting - Colorectal Cancer Clinical Trials

CirculAting Tumor DNA in Patients DIagnosed With Lung Metastasis From Colorectal Cancer: candiDate Selection for Local AblaTive thErapy

CANDIDATE
Start date: February 2021
Phase:
Study type: Observational

The investigators will detect circulating tumor DNA in blood of patients with lung metastases from colorectal cancer using NGS technology and intend to use it for predicting the outcome of local treatment (surgery or radiation) and recurrence of lung metastases.